70:
Sometimes recombinant fusion proteins containing a toxin and a growth factor are also referred to as recombinant immunotoxins, although they do not contain an antibody fragment. A more specific name for this latter kind of protein is recombinant fusion toxin.
122:
cell surface receptor on these leukemic cells. In two uncontrolled clinical studies, about half of participants achieved a complete response after BL22 treatment. This therapeutic has been superseded by
67:
protein derived from a bacterial or plant protein, from which the natural binding domain has been removed so that the Fv directs the toxin to the antigen on the target cell.
138:. This subgroup was Stage IB-IIB with mSWAT scores of less than 50. The complete response rate was 50% (two of which are over 72 months duration and could represent cures).
358:
Angimmune: Clinical Trials: Identification of a
Cutaneous T-Cell Lymphoma (CTCL) Subgroup Experiencing a High Treatment Response Rate: Paragraph 1
180:
300:
79:
They were originally produced by attaching the antibody to the toxin using a chemical linker. They are now made using
35:, and the toxin kills the cell. They are used for the treatment of some kinds of cancer and a few viral infections.
157:
135:
375:
56:
173:
356:
167:
283:
Pastan I, Ho M (2010). "Recombinant immunotoxins for treating cancer.". In
Kontermann R, Dübel S (eds.).
391:
318:"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia"
147:
115:
156:, or A-dmDT390-bisFv(UCHT1), an experimental anti-T cell immunotoxin in clinical trials to treat
112:
339:
296:
265:
226:
44:
17:
329:
288:
257:
218:
80:
222:
371:
385:
176:, most, if not all, are immunotoxins but use whole antibodies and non-protein drugs
64:
292:
118:. These patients were treated with the recombinant immunotoxin which targets the
334:
317:
32:
153:
131:
343:
269:
230:
161:
60:
48:
100:
27:
is an artificial protein consisting of a targeting portion linked to a
111:
The best clinical success has been achieved in treating patients with
261:
245:
206:
52:
28:
103:
on the target cell and the toxin then enters and kills the cell.
124:
119:
134:
found an 89% response rate in a subgroup of nine patients with
31:. When the protein binds to that cell, it is taken in through
316:
Kreitman RJ, Wilson WH, Bergeron K, et al. (July 2001).
244:
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (July 2006).
59:
that targets a specific cell type. The toxin is usually an
205:
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007).
99:
The antibody (or other targeting moiety) binds to an
287:. Berlin, Heidelberg: Springer. pp. 127–146.
51:or antibody fragment, attached to a fragment of a
150:, an immunotoxin used to treat T cell leukemias
200:
198:
8:
55:. The targeting portion is composed of the
83:techniques, are produced in bacteria like
374:at the U.S. National Library of Medicine
333:
194:
181:Immunopharmacology and Immunotoxicology
170:, being tested in hairy cell leukemia
7:
223:10.1146/annurev.med.58.070605.115320
14:
207:"Immunotoxin treatment of cancer"
246:"Immunotoxin therapy of cancer"
127:, a slightly modified version.
47:are usually made of a modified
1:
293:10.1007/978-3-642-01147-4_10
335:10.1056/NEJM200107263450402
408:
130:A recent Phase I study of
57:Fab portion of an antibody
15:
158:cutaneous T-cell lymphoma
136:cutaneous T cell lymphoma
376:Medical Subject Headings
174:Antibody-drug conjugates
89:recombinant immunotoxins
168:Anti-CD22 immunotoxins
285:Antibody Engineering
107:Clinical application
16:For other uses, see
148:Denileukin diftitox
116:hairy cell leukemia
302:978-3-642-01146-7
184:(medical journal)
45:chimeric proteins
18:Immunosuppressant
399:
359:
354:
348:
347:
337:
313:
307:
306:
280:
274:
273:
250:Nat. Rev. Cancer
241:
235:
234:
202:
407:
406:
402:
401:
400:
398:
397:
396:
382:
381:
368:
363:
362:
355:
351:
322:N. Engl. J. Med
315:
314:
310:
303:
282:
281:
277:
262:10.1038/nrc1891
243:
242:
238:
204:
203:
196:
191:
160:and metastatic
144:
109:
97:
81:recombinant DNA
77:
41:
21:
12:
11:
5:
405:
403:
395:
394:
384:
383:
380:
379:
367:
366:External links
364:
361:
360:
349:
308:
301:
275:
236:
211:Annu. Rev. Med
193:
192:
190:
187:
186:
185:
177:
171:
165:
151:
143:
140:
108:
105:
96:
93:
76:
73:
40:
37:
13:
10:
9:
6:
4:
3:
2:
404:
393:
390:
389:
387:
377:
373:
370:
369:
365:
357:
353:
350:
345:
341:
336:
331:
327:
323:
319:
312:
309:
304:
298:
294:
290:
286:
279:
276:
271:
267:
263:
259:
256:(7): 559–65.
255:
251:
247:
240:
237:
232:
228:
224:
220:
216:
212:
208:
201:
199:
195:
188:
183:
182:
178:
175:
172:
169:
166:
163:
159:
155:
152:
149:
146:
145:
141:
139:
137:
133:
128:
126:
121:
117:
114:
106:
104:
102:
94:
92:
90:
86:
82:
74:
72:
68:
66:
62:
58:
54:
50:
46:
38:
36:
34:
30:
26:
19:
392:Immunotoxins
372:immunotoxins
352:
328:(4): 241–7.
325:
321:
311:
284:
278:
253:
249:
239:
214:
210:
179:
129:
110:
98:
88:
84:
78:
69:
42:
24:
22:
33:endocytosis
25:immunotoxin
217:: 221–37.
189:References
113:refractory
75:Production
154:Resimmune
132:Resimmune
65:cytotoxic
386:Category
344:11474661
270:16794638
231:17059365
162:melanoma
142:See also
95:Function
61:AB toxin
49:antibody
101:antigen
87:called
85:E. coli
378:(MeSH)
342:
299:
268:
229:
43:These
39:Design
53:toxin
29:toxin
340:PMID
297:ISBN
266:PMID
227:PMID
125:HA22
120:CD22
63:, a
330:doi
326:345
289:doi
258:doi
219:doi
23:An
388::
338:.
324:.
320:.
295:.
264:.
252:.
248:.
225:.
215:58
213:.
209:.
197:^
91:.
346:.
332::
305:.
291::
272:.
260::
254:6
233:.
221::
164:.
20:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.